Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements

Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements

Background: Approximately 25% of women diagnosed with tubo-ovarian high-grade serous carcinoma have germline deleterious mutations in <i>BRCA1</i> or <i>BRCA2</i>, characteristic of hereditary breast and ovarian cancer syndrome, while somatic mutations have been detected in 3...

Full description

Bibliographic Details
Main Authors: Gulisa Turashvili, Conxi Lazaro, Shengjie Ying, George Charames, Andrew Wong, Krista Hamilton, Denise Yee, Evangeline Agro, Martin Chang, Aaron Pollett, Jordan Lerner-Ellis
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
high-grade serous carcinoma
BRCA
tumor sequencing
PARP inhibitors
Online Access:https://www.mdpi.com/2072-6694/12/11/3468

Internet

https://www.mdpi.com/2072-6694/12/11/3468

Similar Items